252 related articles for article (PubMed ID: 16250877)
1. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
2. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
3. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
5. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
7. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
8. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.
Leslie GJ; Wang J; Richardson MW; Haggarty BS; Hua KL; Duong J; Secreto AJ; Jordon AP; Romano J; Kumar KE; DeClercq JJ; Gregory PD; June CH; Root MJ; Riley JL; Holmes MC; Hoxie JA
PLoS Pathog; 2016 Nov; 12(11):e1005983. PubMed ID: 27855210
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
10. New advances in HIV entry inhibitors development.
Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
[TBL] [Abstract][Full Text] [Related]
11. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
12. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
Liu S; Wu S; Jiang S
Curr Pharm Des; 2007; 13(2):143-62. PubMed ID: 17269924
[TBL] [Abstract][Full Text] [Related]
13. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
[TBL] [Abstract][Full Text] [Related]
14. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
15. [HIV entry into the cells--mechanisms and therapeutic possibilities].
Briz V; Poveda E; Soriano V
Med Clin (Barc); 2006 Mar; 126(9):341-8. PubMed ID: 16650368
[TBL] [Abstract][Full Text] [Related]
16. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
17. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
18. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
19. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
20. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
